Identification of a Prognostic Microenvironment-Related Gene Signature in Glioblastoma Patients Treated with Carmustine Wafers

Identification of a Prognostic Microenvironment-Related Gene Signature in Glioblastoma Patients Treated with Carmustine Wafers

Despite the state-of-the-art treatment, patients diagnosed with glioblastoma (GBM) have a median overall survival (OS) of 14 months. The insertion of carmustine wafers (CWs) into the resection cavity as adjuvant treatment represents a promising option, although its use has been limited due to contra...

Full description

Bibliographic Details
Main Authors: Ivana Manini, Emiliano Dalla, Vera Vendramin, Daniela Cesselli, Carla Di Loreto, Miran Skrap, Tamara Ius
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cancers
Subjects:
glioblastoma
carmustine wafers
tumor microenvironment
patient’ derived in vitro model
transcriptomics
Online Access:https://www.mdpi.com/2072-6694/14/14/3413

Internet

https://www.mdpi.com/2072-6694/14/14/3413

Similar Items